Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A Randomised, Placebo-Controlled Study of Omipalisib (PI3K/mTOR) in Idiopathic Pulmonary Fibrosis.

Lukey PT, Harrison SA, Yang S, Man Y, Holman BF, Rashidnasab A, Azzopardi G, Grayer M, Simpson JK, Bareille P, Paul L, Woodcock HV, Toshner R, Saunders P, Molyneaux PL, Thielemans K, Wilson FJ, Mercer PF, Chambers RC, Groves AM, Fahy WA, Marshall RP, Maher TM.

Eur Respir J. 2019 Feb 14. pii: 1801992. doi: 10.1183/13993003.01992-2018. [Epub ahead of print]

PMID:
30765508
2.

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.

Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Colafrancesco S, Pipi E, Kollert F, Hunter KJ, Brewer C, Buckley CD, Bowman SJ, Priori R, Valesini G, Juarez M, Fahy WA, Fisher BA, Payne A, Allen RA, Barone F.

Ann Rheum Dis. 2019 Feb;78(2):249-260. doi: 10.1136/annrheumdis-2017-212619. Epub 2018 Nov 24.

3.

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants.

Maden CH, Fairman D, Chalker M, Costa MJ, Fahy WA, Garman N, Lukey PT, Mant T, Parry S, Simpson JK, Slack RJ, Kendrick S, Marshall RP.

Eur J Clin Pharmacol. 2018 Jun;74(6):701-709. doi: 10.1007/s00228-018-2435-3. Epub 2018 Mar 12.

4.

The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis.

Usmani OS, Biddiscombe MF, Yang S, Meah S, Oballa E, Simpson JK, Fahy WA, Marshall RP, Lukey PT, Maher TM.

Respir Res. 2018 Feb 6;19(1):25. doi: 10.1186/s12931-018-0732-0.

5.

Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.

Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Bolouri M, Locantore N, Riley JH.

Int J Chron Obstruct Pulmon Dis. 2018 Jan 8;13:203-215. doi: 10.2147/COPD.S145285. eCollection 2018.

6.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG.

Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14.

7.

Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.

Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, Guillen-Guio B, Ma SF, Okamoto T, John AE, Obeidat M, Yang IV, Henry A, Hubbard RB, Navaratnam V, Saini G, Thompson N, Booth HL, Hart SP, Hill MR, Hirani N, Maher TM, McAnulty RJ, Millar AB, Molyneaux PL, Parfrey H, Rassl DM, Whyte MKB, Fahy WA, Marshall RP, Oballa E, Bossé Y, Nickle DC, Sin DD, Timens W, Shrine N, Sayers I, Hall IP, Noth I, Schwartz DA, Tobin MD, Wain LV, Jenkins RG.

Lancet Respir Med. 2017 Nov;5(11):869-880. doi: 10.1016/S2213-2600(17)30387-9. Epub 2017 Oct 20.

8.

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.

Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.

Int J Chron Obstruct Pulmon Dis. 2017 Feb 24;12:745-755. doi: 10.2147/COPD.S119032. eCollection 2017.

9.
10.

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD.

Rheault T, Khindri S, Vahdati-Bolouri M, Church A, Fahy WA.

ERJ Open Res. 2016 Apr 27;2(2). pii: 00101-2015. eCollection 2016 Apr.

11.

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.

Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 24;11:1413-24. doi: 10.2147/COPD.S101612. eCollection 2016.

12.

The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.

Sousa AR, Riley JH, Church A, Zhu CQ, Punekar YS, Fahy WA.

NPJ Prim Care Respir Med. 2016 Jun 23;26:16031. doi: 10.1038/npjpcrm.2016.31.

13.

A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.

Siler TM, Donald AC, O'Dell D, Church A, Fahy WA.

Int J Chron Obstruct Pulmon Dis. 2016 May 9;11:971-9. doi: 10.2147/COPD.S102962. eCollection 2016.

14.

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.

Feldman G, Maltais F, Khindri S, Vahdati-Bolouri M, Church A, Fahy WA, Trivedi R.

Int J Chron Obstruct Pulmon Dis. 2016 Apr 7;11:719-30. doi: 10.2147/COPD.S102494. eCollection 2016.

15.

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.

Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.

Drugs R D. 2016 Jun;16(2):217-27. doi: 10.1007/s40268-016-0131-2.

16.

AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.

Kuna P, Jenkins M, O'Brien CD, Fahy WA.

Respir Med. 2012 Apr;106(4):531-9. doi: 10.1016/j.rmed.2011.10.020. Epub 2011 Dec 23.

17.

Pneumococcal and influenza vaccination in patients with rheumatic conditions and receiving DMARD therapy.

Fahy WA, Farnworth E, Yeldrem KP, Melling GS, Grennan DM.

Rheumatology (Oxford). 2006 Jul;45(7):912-3. Epub 2006 Apr 25. No abstract available.

PMID:
16638800

Supplemental Content

Support Center